Deutsche Märkte schließen in 4 Stunden 42 Minuten

Novan, Inc. (NOVN)

NasdaqCM - NasdaqCM Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
1,7600-0,0800 (-4,35%)
Börsenschluss: 04:00PM EDT

Novan, Inc.

4020 Stirrup Creek Drive
Suite 110
Durham, CA 27703
United States
919 485 8080
https://www.novan.com

Sektor(en)Healthcare
BrancheBiotechnology
Vollzeitmitarbeiter29

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Ms. Paula Brown Stafford M.P.H.Pres, CEO & Chairwoman1,01MN/A1965
Mr. John M. Gay CPACFO & Corp. Sec.482,26kN/A1976
Mr. Brian M. JohnsonChief Commercial Officer443kN/A1966
Mr. John A. Donofrio Jr.Exec. VP, COO & Pres of EPI HealthN/AN/A1967
Mr. Andrew J. NovakVP of Accounting & Bus. Operations and Chief Accounting OfficerN/AN/AN/A
Dr. Carri Geer Ph.D.Sr. VP & CTON/AN/AN/A
Mr. Cole IkkalaDirector of Investor Relations, Communications & Bus. Devel.N/AN/AN/A
Mr. Stanley Hollenbach BS, J.D.Sr. VP of R&DN/AN/AN/A
Dr. Tomoko Maeda-Chubachi M.B.A., M.D., Ph.D.Chief Medical OfficerN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

Corporate Governance

Novan, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.